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Wrath caused by Rath
A recent letter to the Star claimed that differing views about
AIDS were being stifled. In support of this the writer, from the
Treatment Information Group (TIG), cited that the SAMJ had
announced as much in an editorial, and that two articles
submitted for publication that were critical of the scientific
views had been rejected. In response the Journal filled in the
information selectively omitted, including the fact that authors
were advised of the reasons for rejection, inter alia for
containing falsehoods. Searching the website of the TIG
revealed that it had formed a strategic alliance with the Dr
Rath Foundation. Apart from the bizarre therapeutic claims,
the TIG stated that their members had been in telephone
contact with the Minister of Health, who had read all their
documents. If this is true it is a privilege rarely accorded to the
health professions and explains some of the astounding
statements by the Minister, especially concerning the toxicity of
antiretroviral medication.
Were it not so serious for the people of South Africa, the
report by Chris Bateman (p. 372) on some of the effects of the
Rath Foundation shenanigans would be material for a far-
fetched stage farce. 
Childhood eczema consensus
In a recent editorial Dan Ncayiyana critically reviewed the
value of published clinical guidelines (SAMJ December 2004).
From time to time the SAMJ has readily published such
material and in the guise of a ‘consensus document’ we publish
another, by the South African Childhood Atopic Eczema
Working Group, as a Part 2 to this issue. Despite the fact that
the development of good guidelines does not ensure their use
in practice, the following benefits are apparent: (i) in a country
with a small number of experts in various specialties, a
consensus document of this nature is likely to reflect a genuine
‘country view’ of the topic; (ii) since the experts are influential
teachers, the information will be conveyed to large numbers of
undergraduate and postgraduate students; (iii) the reviews of
the topic provide practitioners with valuable update material;
and (iv) funders have an authoritative source to rely on.
The prevalence of atopic eczema (AE) has risen over the past
few decades, though there is a paucity of data on its prevalence
in South Africa. A recent study found that it is very rare in
Xhosa children in rural settlements, and a clear urban/rural
gradient exists for the occurrence of AE in black children. In
children and young adults with an atopic constitution, the
underlying inflammation is dominated by an immunoglobulin
E (IgE) antibody-associated reaction. The diagnosis of AE
cannot be reached without an IgE antibody determination or
skin test. Children with AE have a greater risk of developing
asthma than children with non-atopic eczema. They also have
food allergies and IgE-induced urticaria. Provoking factors for
eczema exacerbations include microbial colonisation, barrier
disruption, environmental exposure, contact, inhalant and
ingestant allergens, sweating, pollutants, sensory irritants
(wool), chemical irritants, and maternal ingestants (in breast-
milk).
Exclusive breast-feeding of high-risk infants for at least 4
months prevents the development of AE. There is no good
evidence that substitution of breast-milk with soya formula
will prevent allergic diseases, although soya milk may be used
as an alternative in infants who have confirmed cow’s milk
allergy. Because of the high prevalence of food allergy in
infants and young children with atopic dermatitis, testing for
food allergy is an essential part in management of the infant. 
The management of atopic dermatitis should comprise
general measures including avoidance of trigger factors,
adjuvant measures and anti-inflammatory therapy. 
Topical steroids have been the cornerstone of AE therapy for
the last 40 years. Systemic antihistamines have been found to
benefit some patients, but the effectiveness is often short-lived.
Topical antihistamine applications may be of use for very short
periods but should not be used chronically. New therapies such
as the topical calciteurin inhibitor pimecrolimus represent
major advances in the management of AE. 
Childhood SLE
Systemic lupus erythematosus (SLE) is a multisystem,
autoimmune disorder characterised by the formation of
antibodies to cellular components. Faller et al. (p. 424)
investigated the demographics and presenting features of
childhood SLE.
Worldwide, 15 - 17% of SLE patients present before 16 years
of age, with a peak incidence at 10 - 14 years. It is rare in
children below 4 years old and there is a female preponderance
in adolescence and adulthood. Warning signs of childhood SLE
include unexplained rash, photosensitivity, Raynaud’s
phenomenon, oral ulcers, arthritis/arthralgia, serositis,
ongoing constitutional symptoms and lymphadenopathy/
hepatosplenomegaly. SLE is also likely if there is multiorgan
involvement.
Their findings suggest that patients in their population are
being missed early on, and therefore present late, and that
childhood SLE is an insidious disease initially. There has been
an increased recognition of the disease in young black South
Africans since 1986.
Playstation thumb
We have published student papers in the past – now read our
first ‘pre-student paper’ (p. 412).
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